GlaxoSmithKline announced that two chronic obstructive pulmonary disease COPD drugs Incruse and Anoro have received a positive opinion from the European Medicines Agency’s EMA Committee for Medicinal Products for Human Use CHMP. A final decision from the European Commission should be out by the end of the next quarter.
Glaxo is looking to get Incruse approved as a once-daily maintenance treatment for symptomatic relief in adults with COPD.
The other COPD drug, Anoro is a combination of Incruse a long-acting muscarinic antagonist/LAMA, umeclidinium bromide/UMEC and another COPD drug from Glaxo, Breo a long-acting beta2 agonist/LABA, vilanterol/VI.
full article: CHMP Positive on Glaxo’s Two Drugs – Analyst Blog – NASDAQ.com.
Don't Forget To Breathe 